Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy

Slides:

Advertisements

Similar presentations

Managing Multiple Medications in Patients with PAH ADAANI FROST, MD Director, Pulmonary Hypertension Center Professor of Medicine Baylor College of Medicine.

Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:

Clinical use of PAH drugs based on functional class

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Exploring Early Combination Therapy in PAH

A Multidisciplinary Team Approach Challenges and Best Practices in Cushing Disease.

Monitoring and Modifying Treatment in PAH

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

A Paradigm Shift in PAH.

An Update on Oral Prostanoids: Advancing Care for PAH?

Optimizing Use of Biological Agents in Ulcerative Colitis

UNDERSTANDING RISK STRATIFICATION IN PAH:

Patient 1: 53-Year-Old Man With CVD Risk Factors

The Latest Data on Oral Prostacyclin Therapy in PAH

Improving Acne Outcomes

How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients

Before and After: Patient Cases in Onychomycosis

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

All About PAH:.

An Interprofessional Approach to the Patient With Chronic Airway Disease.

When Would You Use Single Inhaler Triple Therapy in COPD?

Follow-Up of the Patient After PE

PAH Therapy Revisited.

PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence

Improving Risk Assessment and Early Diagnosis in PAH

Updates in Pulmonary Arterial Hypertension

WHO Clinical Classification of PH Complex Cases in PH.

Selected Highlights of the Latest Advances in PAH

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Evolving Science of PAH Treatment

Should I Stay or Should I Go?

Risk Assessment in PAH.

Examining the Latest Evidence in PAH

Poor Response to Initial Therapy for Migraine

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea

The Evolving Treatment Landscape in Atopic Dermatitis

Oral Prostanoids and PAH

Preventing Clinical Events in PAH

PAH and Prostacyclin Pathways in Focus

Guide to Atopic Dermatitis

Pulmonary Arterial Hypertension and Connective Tissue Disease

What's New in PAH?.

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

Oral Prostacyclin Pathway Agents in PAH

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

Group 1 PAH: Current Therapies

Critical Decision Points in Insomnia

Incorporating Prostacyclins Into Practice

Joint BES/BBS Seminar Sequential vs initial combination therapy in a rare disease Presenter: Evan Davies 22nd November 2018.

Improving Adherence to Antiplatelet Therapy After an ACS Event

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Live on PAH: Breathing Life Into Patients With PAH

When Good Isn't Good Enough

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Optimal Treatment of PAH

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Prostacyclin Pathway Agents in Action

Transitioning Therapy in PAH: Practical Strategies and Considerations

Incorporating New PAH Treatments Into Clinical Practice

PAH Pathways: What Do the Data Tell Us?”

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

What's New in PAH?.

My PAH Patient.

Presentation transcript:

Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy

Program Themes

Case Study: 42-Year-Old Woman, 6-Month Follow-Up of Her PAH

Clinical Course

Clinical Course January 2015

Therapies Targeting the PGI2 Pathway

Therapeutic Decision January 2015

Today’s Evaluation

Adherence With Inhaled Prostanoids

GRIPHON Treatment Effect by Subgroup

Right Heart Catheterization

Transitioning From Inhaled to Oral Prostacyclin Pathway Agent

Transition From Inhaled Treprostinil to Oral Selexipag

AMBITION Ambrisentan + Tadalafil vs Monotherapy in Treatment-Naive Patients With PAH

Initial Triple Therapy

Conclusions

Abbreviations